Clearside Biomedical, headquartered in Alpharetta, Georgia, specializes in therapies delivered to the eye via the suprachoroidal space and has developed the approved product XIPERE. The company’s lead program, CLS-AX, is in Phase 2b clinical testing for wet AMD.
Clay Thorp bought 15,000 shares of CLSD on 24 February at $0.92 per share, worth a total of $14K. They now own 176,141 CLSD shares, or a 9% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
